LUND, Sweden, Nov. 26, 2021 /PRNewswire/
-- Immunovia AB (publ) announces that Tobias Bülow has
been appointed new Senior Director Investor Relations and Corporate
Communications, taking up his position January 15. Tobias has s solid IR and Corporate
Communications background with extensive experience from
international high-tech companies.
Tobias joins Immunovia from Mycronic AB (publ), where he most
recently held the position of Director Investor Relations. Previous
experiences include Director Financial Communications at the
radiation therapy company Elekta AB (publ).
"I am very pleased to welcome Tobias to Immunovia and the role
as Senior Director Investor Relations and Corporate Communications.
Tobias has a solid international background from leading positions
and companies. I am convinced he has the drive, skills, and
experience to contribute in shaping Immunovia's continued journey,"
says Patrik Dahlen, CEO of
Immunovia.
For more information, please contact:
Patrik Dahlen, CEO Immunovia
Email: patrik.dahlen@immunovia.com
Tel: +46 73 376 76 64
About Immunovia
Immunovia AB is a diagnostic company that is developing and
commercializing highly accurate blood tests for the early detection
of cancer based on Immunovia's proprietary test platform
called IMMray™. Tests are based on antibody biomarker
microarray analysis using advanced machine-learning and
bioinformatics to single-out a set of relevant biomarkers that
indicate a certain disease. Thus, forming a unique "disease
biomarker signature".
The company was founded in 2007, based on cancer studies and
ground-breaking research in the Department of Immuntechnology at
Lund University and CREATE Health
Cancer Center, Sweden.
The first product, IMMray™ PanCan-d, is undergoing clinical
evaluation in some of the world's largest clinical studies for
high risk groups in pancreatic cancer, PanFAM-1, PanSYM-1 and
PanDIA-1.
In 2017, Immunovia, Inc. was established in Marlborough, Massachusetts, USA. The IMMray™
PanCan-d test, the first blood-based test dedicated to the early
detection of pancreatic cancer on the market, is offered as a
laboratory developed test (LDT) exclusively through Immunovia, Inc.
For more information see: www.immunoviainc.com.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/immunovia-ab/r/immunovia-appoints-new-senior-director-investor-relations-and-corporate-communications,c3461283
The following files are available for download:
https://mb.cision.com/Main/13121/3461283/1502042.pdf
|
Press release
(PDF)
|
View original
content:https://www.prnewswire.com/news-releases/immunovia-appoints-new-senior-director-investor-relations-and-corporate-communications-301432301.html
SOURCE Immunovia AB